GLP-1, ,
While these are different trials with different designs and not a direct head-to-head comparison, the data suggests retatrutide may deliver greater weight loss
Genital Mycotic Infections In the glycemic control trials in adults, genital mycotic infections were more frequent with dapagliflozin treatment
In fact, Saxenda (liraglutide) has been approved by the FDA for use in weight management in people with a BMI of 30 or higher or a BMI of 27 or higher with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol
The largest individual exposures in this window include: Mercks pembrolizumab (Keytruda), with $25 billion in 2023 revenue, faces composition of matter patent expiry in 2028, though secondary patents on specific dosing methods, combination regimens, and PD-1 binding domains extend the formal portfolio timeline
Participants receiving the highest dose of 12 mg lost an average of 24.2% of their body weight, compared to just 2.1% with placebo